Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Fragoso Y. D., Spelman T., BOZ C., Alroughani R., Lugaresi A., Vucic S., ...More

MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.19, pp.105-108, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19
  • Publication Date: 2018
  • Doi Number: 10.1016/j.msard.2017.11.018
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.105-108
  • Keywords: Fingolimod, Lymphocytes, Multiple sclerosis, Relapses, Disability, MULTIPLE-SCLEROSIS, FTY720
  • Karadeniz Technical University Affiliated: Yes


Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed in a wide range of cells, including lymphocytes. Under the effect of fingolimod, lymphocytes are retained in lymphoid tissues through the regulation of S1P(1) receptors. The aim of the present study was to assess whether the degree of lymphopenia was correlated to the positive treatment response of RRMS patients with fingolimod.